Chronic Myeloid Leukemia

51st ASH Annual Meeting and Exposition (December 5-8, 2009) __________________________________________________________________________________________
Chronic Myeloid Leukemia: After a Decade of Imatinib
Chronic Myeloid Leukemia - Biology and Pathophysiology excluding Therapy: New Molecular Mechanisms in CML
Chronic Myeloid Leukemia - Biology and Pathophysiology excluding Therapy: Progenitor and Stem Cells in CML
Chronic Myeloid Leukemia - Biology and Pathophysiology excluding Therapy: New Insights into the Molecular Biology of CML
Chronic Myeloid Leukemia - Biology and Pathophysiology excluding Therapy Poster I
Chronic Myeloid Leukemia - Therapy: Initial Therapy
Chronic Myeloid Leukemia - Therapy: New Trends in Management
Chronic Myeloid Leukemia - Therapy: Managing Resistance and Residual Disease
Chronic Myeloid Leukemia - Therapy: New Trends in Management
Chronic Myeloid Leukemia - Therapy Poster I
___________________________________________________________________________________________

ASH 2009 Recollections - and why I went there again.
Written by Jan Geissler, Director, European Cancer Patient Coalition
Tuesday, 15 December 2009
 
ASH 2009 New Orleans Highlights
Cheryl-Anne Simoneau, president of the CML Society of Canada
____________________________________________________________________________________________
SOME VIDEOS by PatientPower.info

Fighting Drug Resistance: The CML Example
Dr. Richard Larson talks about patients concerns over drug resistance and the role of old drugs

More Powerful Therapy Upfront
Dr. Michael Mauro discusses first line drugs, second line drugs and changing strategies for treating patients with CML.

Vaccine Therapy for Blood Related Cancers
Dr. Carl June discusses promising research surrounding vaccine therapy for patients with blood related cancers.

On the Horizon: Chemo Drugs No Longer Needed?
Dr. Ronald Levy talks about the possibility of no longer needing chemo and the role of antibodies.

Research on the Horizon for Hematologic Malignancies
Dr. Alan Gewirtz discusses research and new strategies for harnessing the immune system.
____________________________________________________________________________________________

Tyrosine Kinase Inhibitors in CML: Applying New Data to Practice -- An Expert Interview With Dr. Elias J. Jabbour From ASH 2009
2009, Medscape Education

______________________________________________________________________________________________